Stockscreener 앱 받기
1.26
0.00%
0.00
전일 마감가:
$1.26
열려 있는:
$1.29
하루 거래량:
101.68K
Relative Volume:
0.44
시가총액:
$6.03M
수익:
$17.72M
순이익/손실:
$-3.37M
주가수익비율:
-0.6183
EPS:
-2.038
순현금흐름:
$-3.72M
1주 성능:
+4.13%
1개월 성능:
+15.60%
6개월 성능:
-65.48%
1년 성능:
-68.02%
1일 변동 폭
$1.22
$1.29
1주일 범위
$1.185
$1.31
52주 변동 폭
$0.8501
$6.9199
소노마 파머 Stock (SNOA) Company Profile
명칭
Sonoma Pharmaceuticals Inc
전화
800-759-9305
주소
5445 CONESTOGA COURT, SUITE 150, BOULDER, CA
Compare SNOA vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNOA
Sonoma Pharmaceuticals Inc
|
1.26 | 6.03M | 17.72M | -3.37M | -3.72M | -2.038 |
TAK
Takeda Pharmaceutical Co Adr
|
16.56 | 52.88B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.76 | 42.98B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.95 | 38.37B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.56 | 31.68B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
547.06 | 23.22B | 3.17B | 1.29B | 1.01B | 27.09 |
소노마 파머 주식(SNOA)의 최신 뉴스
Form 4 Sonoma Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com South Africa
Sonoma Pharmaceuticals (NASDAQ: SNOA) awards CEO 10,000 RSUs in equity grant - Stock Titan
Enterprise value to EBIT forward of Sonoma Pharmaceuticals, Inc. – NASDAQ:SNOA - TradingView
Price to book forward of Sonoma Pharmaceuticals, Inc. – FWB:O8Z - TradingView
Price to sales forward of Sonoma Pharmaceuticals, Inc. – FWB:O8Z - TradingView
SNOA Should I Buy - Intellectia AI
Sonoma Pharmaceuticals (SNOA) Secures FDA Clearance for Microdac - GuruFocus
Sonoma Pharmaceuticals receives FDA clearance for wound solution - Investing.com
Sonoma Pharmaceuticals receives FDA clearance for wound solution By Investing.com - Investing.com Canada
Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation Solution - ACCESS Newswire
Sonoma Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:SNOA) - TradingView
Sonoma Pharmaceuticals Inc (SNOA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Sonoma Pharmaceuticals Inc (SNOA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Sonoma Pharmaceuticals Expands At-the-Market Equity Offering Capacity - The Globe and Mail
Sonoma Pharmaceuticals Inc (SNOA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Sonoma Pharmaceuticals Files 8-K for $3.6 Million Common Stock Offering – Nasdaq: SNOA, June 2026 - Minichart
According to a recent filing submitted to the U.S. Securities and Exchange Commission (SEC), Sonoma Pharmaceuticals, Inc. has raised the maximum total offering price of its common stock issuance to $3.64 million. - Bitget
Sonoma Pharmaceuticals increases at-the-market offering to $3.64 million - Investing.com UK
Sonoma Pharmaceuticals increases at-the-market offering to $3.64 million By Investing.com - Investing.com Nigeria
Sonoma Pharmaceuticals Inc - TradingKey
Sonoma Pharmaceuticals boosts shelf offering capacity to $3.64M after prior $574.6K sales - TradingView
[8-K] Sonoma Pharmaceuticals, Inc. Reports Material Event - Stock Titan
Sonoma Pharmaceuticals Inc (SNOA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Sonoma Pharmaceuticals Inc (SNOA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Sonoma Pharmaceuticals Inc (SNOA) Institutional Confidence - TradingKey
Sonoma Pharmaceuticals Inc (SNOA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Sonoma Pharmaceuticals Q4 revenue rises 48% on US growth - TradingView
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results - ACCESS Newswire
BRIEF-Sonoma Pharmaceuticals Q4 Net Income USD -600 Thousand - TradingView
Sonoma Pharmaceuticals, Inc. FY 2026: Revenue $19.5M, EPS $(1.89) — 10-K Summary - TradingView
Sonoma Pharmaceuticals | 10-K: FY2026 Annual Report - Moomoo
Sonoma Pharmaceuticals (NASDAQ: SNOA) outlines global HOCl strategy and risks - Stock Titan
SNOA Q1 2026 Earnings: EPS Misses Estimates Amid Operational and Revenue Disclosures - newsline.com
Sonoma Pharmaceuticals Q1 2026 Earnings: EPS Miss Triggers Sharp SelloffCFO Commentary Report - newsline.com
Sonoma Pharmaceuticals Inc. (SNOA) Q1 2026 Earnings: EPS Falls Short of Estimates, Stock Unchanged - newsline.com
SNOASonoma Pharmaceuticals Inc Stock Price and Quote - Finviz
Sonoma Pharmaceuticals (SNOA) Edges Higher, Testing Resistance at $1.13Channel Breakout - The Legal Advocate
SNOA Q1 2026 Earnings: EPS Misses Estimates as Revenue Remains UnreportedEnergy Earnings Report - newsline.com
Sonoma Pharmaceuticals Inc. (SNOA) Q1 2026 Earnings: EPS Slightly Misses Estimates Amid Thin Revenue DisclosuresOne-Time Gain Impact - newsline.com
Sonoma Pharmaceuticals (SNOA) Edges Higher, Testing Key Resistance at $1.13Volatility Smirk - Newser
SNOA SEC FilingsSonoma Pharmaceu 10-K, 10-Q, 8-K Forms - Stock Titan
Sonoma Pharmaceuticals (SNOA) Slips -3.56%, Testing $1.08 Support 2026-05-15Fast Rising Stocks - Newser
Sonoma Pharmaceuticals (SNOA) Q1 2026 Earnings Miss by Significant: Key TakeawaysRevenue Guidance Update - Newser
SNOA Director Jacoby Vanessa Stock Option Filing, May 14, 2026 - Meyka
Sonoma Pharmaceuticals (SNOA) outlines plan to reincorporate from Delaware to Nevada - Stock Titan
Sonoma Pharmaceuticals Completes Equity Offering to Raise Capital - The Globe and Mail
Sonoma Pharmaceuticals Prices $1.35 Unit Offering, Nets ~$3.5M Under Underwriting With Dawson James - TradingView
Sonoma Pharmaceuticals (NASDAQ: SNOA) closes $4M stock and warrant sale - Stock Titan
SNOA Sonoma Pharmaceuticals reports narrow Q1 2026 EPS miss as shares rise 1.92 percent on mild positive investor sentiment.Cost Advantage - Newser
SNOA Director Jacoby Vanessa Stock Option Filing, April 28, 2026 - Meyka
Sonoma Pharmaceuticals registers HOCl facial spray under U.S. cosmetics law - MSN
소노마 파머 (SNOA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.42%
0.81%
자본화:
|
볼륨(24시간):